Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8374733 | 0.82 | ADORA2A (0.44) | GLSCYP1A2KDM4EALDH1A1LMNA | |
| SCHEMBL19557911 | 0.80 | GLS (0.41) | GLSKDM4EALDH1A1LMNAGAA | |
| SCHEMBL24884378 | 0.79 | NOS2 (0.39) | GLSKDM4EALDH1A1LMNAGAA | |
| SCHEMBL24884346 | 0.79 | NOS2 (0.39) | GLSKDM4EALDH1A1LMNAGAA | |
| SCHEMBL621968 | 0.79 | GLS (0.64) | GLSKDM4EALDH1A1LMNAGAA | |
| SCHEMBL31052600 | 0.78 | KDM4E (0.41) | GLSKDM4EALDH1A1LMNAGAA | |
| SCHEMBL21960875 | 0.78 | GLS (0.37) | GLSKDM4EALDH1A1LMNAGAA | |
| SCHEMBL31052692 | 0.78 | KDM4E (0.45) | GLSKDM4EALDH1A1LMNAPKM | |
| SCHEMBL24884330 | 0.77 | GLS (0.39) | GLSKDM4EALDH1A1LMNAGAA | |
| SCHEMBL20555748 | 0.77 | GAA (0.43) | GLSKDM4EALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332905-A | (S) -N-phenyl-1- (pyridin-2-yl) pyrrolidine-2-carboxamide derivatives | 上海翊石医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | Kronos Bio, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | Kronos Bio, Inc. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10344018-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | ELI LILLY AND COMPANY (US) | 2019-07-09 | — | — | US | disclosed |
| US-10323019-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | ELI LILLY AND COMPANY (US) | 2019-06-18 | — | — | US | disclosed |
| US-20190177300-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | LILLY CO ELI (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2019-04-25 | — | — | US | disclosed |
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2019-04-25 | — | — | US | disclosed |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2017-04-06 | — | — | US | disclosed |
| EP-2545052-B1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2545052-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | GLS 1369/4885CYP1A2 3601/4885KDM4E 1920/4885 |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | GLS 1369/4885CYP1A2 3601/4885KDM4E 1920/4885 |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | GLS 1369/4885CYP1A2 3601/4885KDM4E 1920/4885 |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | GLS 1396/4885CYP1A2 3297/4885KDM4E 1839/4885 |
| US-20190177300-A1 | PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS | JAK3, JAK2, JAK1 | GLS 1244/4885CYP1A2 2080/4885KDM4E 1390/4885 |
| US-10344018-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | JAK3, JAK2, JAK1 | GLS 1244/4885CYP1A2 2080/4885KDM4E 1390/4885 |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | GLS 1396/4885CYP1A2 3297/4885KDM4E 1839/4885 |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | GLS 1369/4885CYP1A2 3601/4885KDM4E 1920/4885 |
| US-10323019-B2 | Pyrazolylaminobenzimidazole derivatives as JAK inhibitors | JAK3, JAK2, JAK1 | GLS 1244/4885CYP1A2 2080/4885KDM4E 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.